9 terminated. 9 Phase 3, 2 Phase 2.
By phase and status
Follow CSL Behring: new trials by email
Trials (filtered) newest first · largest first
All 9 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS IgPro20, Placebo - Post-COVID Postural Orthostatic Tachycardia Syndrome Phase 3 Terminated 16 2024-08-28 2026-04-13 Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( TAP Study ) BE1116, Placebo - Traumatic Injury Phase 3 Terminated 1366 2023-03-28 2025-12-10 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM) human immunoglobulin G, Placebo - Dermatomyositis Phase 3 Terminated 134 2019-10-21 2025-12-09 Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients Clazakizumab, Physiologic saline solution - Antibody-mediated Rejection Phase 3 Terminated 194 2019-10-14 2025-07-23 The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant AAT, Placebo - Acute-graft-versus-host Disease Phase 2 / Phase 3 Terminated 222 2019-03-27 2026-09-09 Administration of Prothrombin Complex Concentrate vs. Standard Transfusion During/After Heart Transplantation Kcentra, Frozen Plasma Product, Human - Heart Disease End Stage, Heart Failureļ¼Congestive Phase 3 Terminated 14 2018-07-11 2025-05-23 Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients C1-esterase inhibitor, Placebo - Antibody-mediated Rejection Phase 3 Terminated 63 2017-11-06 2022-07-29 Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors CSL689, Eptacog alfa (activated) - Hemophilia A With Inhibitors, Hemophilia B With Inhibitors Phase 2 / Phase 3 Terminated 25 2015-07-23 2019-08-28 Study of Biostate for Treatment of Children With Hemophilia A Complicated by Antibody Development Biostate - Hemophilia A Phase 3 Terminated 1 2012-12-01 2017-10-03
Conditions studied Dermatomyositis (1) · Heart Failure (1) · Hemophilia A (1) · Wounds and Injuries (1)
Interventions Hizentra (2) · Complement C1 Inhibitor Protein (1) · Factor IX (1) · Factor VII (1) · Respreeza (1) · alpha 1-Antitrypsin (1) · clazakizumab (1) · factor IX, factor VII, factor X, prothrombin drug combination (1) · gamma-Globulins (1)
Countries United States (7) · Germany (5) · Spain (5) · Italy (4) · Australia (3) · Belgium (3) · France (3) · Russia (3) · United Kingdom (3) · Austria (2) · Canada (2) · Hungary (2) · Japan (2) · Netherlands (2) · South Korea (2)
Top investigators Carmen Escuriola-Ettingshausen (1) · Kathirvel Surbramaniam, MD (1) · Kenichi Tanaka, MD (1)
Results publications PMID 33332922 , PMID 35497778 , PMID 35969004 , PMID 36550562 , PMID 39102302 , PMID 40444214
NIH funding 2018 (3) , 2023 (2) , 2017 (1)